Introduction
The p53 tumor suppressor gene plays a pivotal role in the prevention of cancer. Consequently, it is often a target of genetic alterations in tumors: about half of all human tumors carry direct alterations within the p53 locus, and in many of the other half, p53 function is impaired owing to mutations in proteins operating either upstream or downstream to p53 (Vogelstein et al., 2000; Ryan et al., 2001; Michael and Oren, 2002; Bargonetti and Manfredi, 2002) .
p53 exerts its tumor suppressor function through multiple mechanisms. However, the most prominent biochemical feature of p53, underlying the major part of its tumor-suppressor activities, is its ability to act as a sequence-specific transcription factor. This entails direct binding to specific target sequences within the DNA, denoted p53 response elements (p53REs), with consequent transcriptional activation of genes residing in the close vicinity of the p53REs. The importance of the transcriptional activity of p53 is underscored by the finding that the vast majority of p53 mutations encountered in cancer reside within the core sequencespecific DNA-binding domain of p53 (el-Deiry, 1998; Soussi, 2000) . In addition, p53 can also repress the transcription of many other genes, although direct binding of p53 to specific sequences within such genes has not been implicated in most cases. Given p53's pivotal role in tumor suppression, it is therefore logical that potentially tumorigenic cells should strive to inactivate p53, thereby eliminating an important stumbling block for the development of cancer. However, unlike other tumor suppressor genes, such as Rb (Harbour and Dean, 2000) or ARF (Serrano, 2000) , which are typically deleted, truncated, silenced or otherwise downregulated in many cancers, selective pressures within tumors clearly favor missense mutations in p53 rather than its outright elimination, often leading to the constitutive expression of high amounts of mutant p53 in tumor cells (Sigal & Rotter, 2000) . This evidence may suggest p53 mutations to be a doubleedged sword; that is mutant p53 proteins may not only lose the tumor suppressor functions of wild-type p53 (wt p53), but may also acquire additional pro-oncogenic roles (Michalovitz et al., 1991) . Indeed, different forms of mutant p53 vary with regard to their biological capabilities (Halevy et al., 1990) , and there is now ample evidence that common tumor-associated p53 mutants often possess novel oncogenic 'gain of function' activities (Sigal and Rotter, 2000; Cadwell and Zambetti, 2001) . Of note, mutant p53 has been shown to have oncogenic properties in cells which are p53 null, ruling out the simple possibility of a dominant-negative effect over endogenous wt p53 (Dittmer et al., 1993; Wang et al., 1998; Liu et al., 2000) . Several biochemical and biological functions of mutant p53 proteins, independent of the wt p53 protein, have been described. For instance, p53 mutants were shown to be potent activators of numerous genes, including c-Myc (Frazier et al., 1998) , topoisomerase I (Albor et al., 1998) , MDR-1 (Chin et al., 1992; Zastawny et al., 1993; Sampath et al., 2001) , the antiapoptotic BAG-1 (Yang et al., 1999) , as well as of various viral promoters (Deb et al., 1992) . Mutant p53 was also shown to promote genomic instability (Murphy et al., 2000) and to contribute to the disruption of spindle checkpoint control (Gualberto et al., 1998) . Tumor-associated p53 mutants were shown to effectively block apoptosis induced by survival factor deprivation (Peled et al., 1996) , and significantly were also found to be effective inhibitors of DNA damage-induced apoptosis (Lotem & Sachs, 1995; Li et al., 1998; Blandino et al., 1999; Matas et al., 2001) . However, the exact molecular mechanisms underlying the various gain of function activities of mutant p53 still remain to be resolved.
CD95(Fas/APO-1) is a type I transmembrane death receptor, shown to be crucial in a variety of physiological and pathological conditions leading to apoptosis (Walczak and Krammer, 2000) . The apoptotic pathway regulated by CD95 is triggered in response to engagement of this receptor by its cognate ligand, CD95L. A role for CD95 in p53-mediated apoptosis has been proposed on the basis of the observation that the CD95 gene is a transcriptional target of wt p53 (Owen-Schaub et al., 1996) , whose expression is induced through the binding of wt p53 to a regulatory region residing within its first intron, with a possible contribution also of sequences within the CD95 upstream promoter (Muller et al., 1998; Munsch et al., 2000) . Furthermore, there is evidence that CD95 function is required for optimal cell killing by DNA-damaging agents (Friesen et al., 1996; Muller et al., 1997; Embree-Ku et al., 2002) , although this may hold only for some cell types and not for others (Newton and Strasser, 2000) . Interestingly, while it is anticipated that the activation of wt p53 by DNA damage and other types of chemotherapy can trigger CD95 expression in a manner that may contribute to cell killing by these agents, CD95 has been shown to play a role in the cytotoxic effects of anticancer agents also in cells lacking wt p53 (O'Connor et al., 2000; Shao et al., 2001) . Hence, downregulation of CD95 expression in such tumor cells is likely to render them more resistant to chemotherapy.
With this reasoning in mind, we asked whether mutant forms of p53 known to possess an antiapoptotic gain of function can modulate the expression of the CD95 gene. We report here that overexpression of mutant p53 confers partial protection against CD95L-induced apoptosis, and that this is correlated with a significant reduction in CD95 mRNA and surface protein levels. Moreover, evidence is provided that mutant p53 can downregulate the activity of the CD95 promoter, in a manner probably entailing a physical interaction between mutant p53 and DNA sequences within the promoter. These findings suggest a novel mechanism for the antiapoptotic gain of function activity of mutant p53, which may contribute to cancer progression and therapy resistance.
Results

Mutant p53 attenuates CD95-induced apoptosis in PC3 cells
Mutant p53 overexpression can attenuate apoptosis in p53 null cells following DNA damage or deprivation of survival factors (Lotem and Sachs, 1995; Kremenetskaya et al., 1997; Li et al., 1998; Blandino et al., 1999; Matas et al., 2001) . This argues in favor of an antiapoptotic gain of function activity of mutant p53. In an attempt to elucidate the underlying mechanisms, we explored the possibility that mutant p53 may interfere with one or more endogenous apoptotic pathways. The CD95(Fas/APO-1) pathway has been proposed to contribute to the killing of tumor cells by DNA-damaging agents, at least under some circumstances (Friesen et al., 1996; Muller et al., 1997) . We therefore asked whether overexpression of tumorassociated mutant p53 can affect cell killing by the CD95 pathway. The analysis was performed in p53-null human prostate carcinoma PC3 cells, which are reasonably sensitive to CD95-mediated apoptosis.
To assess the impact of mutant p53 on CD95-mediated apoptosis, PC3 cells were infected with a recombinant retrovirus encoding the p53R175 H mutant, shown to exert a potent antiapoptotic gain of function effect (Blandino et al., 1999) . Staining of fixed cells with p53-specific antibodies revealed that over 90% of the cells in the infected culture expressed easily detectable mutant p53 (data not shown). Following 8 h of exposure to a conditioned medium containing CD95 ligand (CD95L) in the presence of the protein synthesis inhibitor cycloheximide (CHX), the rate of cell death was determined by propidium iodide (PI) uptake. As seen in Figure 1a and b, the extent of PI uptake was markedly reduced in PC3 cells infected with p53R175 H, as compared to control p53-null counterparts. Hence, overexpression of tumor-associated mutant p53 can attenuate the induction of CD95-mediated cell death.
Mutant p53 downregulates CD95 mRNA and protein
One possible way in which mutant p53 might attenuate CD95-dependent apoptosis is by downregulating the expression of the CD95 receptor itself. We therefore investigated the effect of overexpressed p53R175 H on the levels of endogenous CD95 mRNA and protein.
Real-time PCR analysis revealed a significant reduction in the amount of CD95 mRNA in PC3 cells stably expressing the mutant p53 (Figure 2 ). Although the reduction was relatively mild, it was highly reproducible in multiple experiments (data not shown). Importantly, FACS analysis revealed that overexpression of mutant p53 also led to a measurable decrease in the amount of CD95 death receptor displayed on the cell surface ( Figure 3 ). In agreement with the RNA data, the decrease was only partial and did not result in complete ablation of CD95 surface protein expression. This observation is also consistent with the fact that the mutant p53 expressors exhibit only a delay in the induction of CD95-mediated apoptosis, rather than being completely refractory to it (Figure 1 ).
Mutant p53 represses the CD95 promoter
The downregulation of CD95 mRNA by mutant p53 might be due to repression of the CD95 gene promoter.
This possibility was explored in transient transfection assays, employing a plasmid in which the expression of a luciferase reporter gene is driven by regulatory DNA elements derived from the human CD95 gene. More specifically, these regulatory sequences include the CD95 promoter, followed by a region from intron 1 of that gene encompassing the p53REs (Muller et al., 1998) . This plasmid is denoted CD95(P þ I)-luc according to the terminology of Muller et al. (1998) . For the sake of simplicity, unless otherwise stated, it will be designated CD95-luc in the following sections.
As seen in Figure 4a , cotransfection of p53R175 H significantly reduced CD95-luc activity in PC3 cells, supporting the conjecture that mutant p53 can indeed repress CD95 gene transcription, and that this repression is responsible for the reduced levels of CD95 mRNA and protein and for the reduced susceptibility to CD95-mediated apoptosis.
Different tumor-associated p53 mutants vary in the extent of their antiapoptotic gain of function; for instance, whereas p53R175 H protects transfected p53-null cells very efficiently against etoposide-induced death, the p53R273 H mutant does so less efficiently (Blandino et al., 1999) . We therefore compared the abilities of these two hot-spot mutants to repress the Figure 1 Mutant p53 reduces the rate of CD95-induced apoptosis. PC3 cells were stably transfected with a plasmid encoding the mouse ecotropic receptor and selected for 2 weeks with 0.4 mg/ml G418. The cells were subsequently infected with a retrovirus expressing mutant p53 (p53R175 H) and selected for 48 h in a medium containing 4 mg/ml puromycin. Infected (175 H) and noninfected (ctrl) cells were seeded in six-well culture dishes, and exposed 24 h later to a conditioned medium containing secreted CD95L, in the presence of 2 mg/ml CHX. Cells were collected 8 h later, incubated with 1 mg/ml PI and subjected to FACS analysis. (a) depicts actual PI-exclusion staining data for a single experiment with cells exposed to 25% CD95L-containing medium; R1 and R2 represent the PI-negative and PI-positive subpopulations, respectively. (b) shows a compilation of PI exclusion data from several runs under identical conditions Figure 2 Mutant p53 downregulates CD95 mRNA. PC3 cells infected with a retrovirus expressing mutant p53 (p53 175 H), as well as control PC3 cells, were seeded in 6 cm culture dishes. After 24 h, cells were harvested and total RNA was extracted. In total, 2 mg of each RNA was used as a template for reverse transcription by MMLV reverse transcriptase. Real-time PCR (Lightcycler, Roche) was performed with primers specific for either CD95 or GAPDH mRNA, the latter serving as a normalization reference. Relative CD95 mRNA levels were calculated by normalization of the CD95 value for the amount of GAPDH transcripts in the same sample Each well was transfected with 0.2 mg of CD95-luc, a reporter plasmid expressing the firefly luciferase gene under the transcriptional control of the CD95 gene regulatory region, which comprises the CD95 promoter as well as a segment of the first intron encompassing the previously described p53RE (Muller et al., 1998) , together with 25 ng of one of the following plasmids: pCMV-neo-Bam vector control (cont), mutant p53R175 H expression plasmid (175 H), and mutant p53R273 H expression plasmid (273 H). Luciferase activity was assayed 48 h post-transfection. Each plasmid combination was transfected into six identical wells; the average and standard error are shown. (b) H1299 lung adenocarcinoma cells were seeded as in (a). Each well was transfected with a CD95 luciferase reporter as in (a), together with 300 ng of one of the following plasmids: pCMV-neo-Bam vector control (cont), mutant p53R175 H expression plasmid (175 H), and a plasmid encoding a derivative of p53R175 H with two-point mutations in the transactivation domain (22, 23) . (c) Extracts from transfections in (b) were assayed for p53 protein expression by Western blot analysis with p53-specific antibodies. (d) H1299 cells were seeded and transfected as in (b) with a CD95 luciferase reporter together with either a control plasmid (cont), or plasmids encoding the 175 H, 273 H or 248W p53 mutants. (e) Extracts from transfections in (d) were assayed for p53 protein expression by Western blot analysis with p53-specific antibodies. (f) H1299 cells, seeded as in (a), were transfected with 0.2 mg of either CD95(P þ I)-luciferase (referred to as CD95-luc in the previously described experiments) or CD95(Ps)-luciferase (f) upper panel, described in Muller et al., 1998) , together with 0.3 mg of either pCMV-neo-Bam (cont) or expression plasmid encoding p53R175 H. Briefly, the CD95(P þ I) construct contains the CD95 promoter as well as the p53RE (indicated by a box) located in the gene's first intron, while the CD95 (Ps) construct contains only the CD95 promoter CD95 promoter. Although p53R273 H was still capable of repressing the CD95 promoter, it did so less efficiently than p53R175 H (Figure 4a and d) , supporting the existence of a correlation between the antiapoptotic activity of a given p53 mutant and its ability to downregulate the CD95 promoter.
It has been shown that the cytoprotective effects of mutant p53 rely on the integrity of its N-terminal transactivation domain (Matas et al., 2001) . We therefore tested whether a mutant p53 protein impaired in this transactivation domain can still repress the CD95 promoter efficiently. These experiments were performed in human lung adenocarcinoma H1299 cells, which like PC3 are also p53-null. As shown in Figure 4b , a derivative of p53R175 H carrying point mutations at residues 22 and 23, which incapacitate the transactivation domain (Lin et al., 1994) , was also impaired in repression of the CD95 promoter, although the levels of mutant p53 protein achieved in the transfected cells were comparable for both mutants (Figure 4c) . Thus, the integrity of the N-terminal transactivation domain is important for the ability of mutant p53 to repress CD95 promoter activity as well as for its ability to protect tumor cells from drug-induced apoptosis.
Another common tumor-associated p53 mutant is p53R248W. Like p53R273 H, the p53R248W hot-spot mutant was also capable of partial repression of the CD95 promoter, albeit not as efficiently as p53R175 H (Figure 4d ) when expressed at comparable levels ( Figure 4e) .
The reporter plasmid employed in all the previous experiments contains a combination of the CD95 promoter and an additional genomic DNA fragment derived from intron 1 of the CD95 gene [CD95(P þ I); Muller et al., 1998 ]. This intronic DNA fragment contains a potent p53-binding site, and is primarily responsible for the activation of the CD95 gene by wt p53 (Muller et al., 1998) . Surprisingly, a reporter plasmid containing only the CD95 promoter, without addition of the intronic p53RE [CD95(Ps), Figure 4f ], was still repressed by mutant p53. Thus, the potential for mutant p53-mediated repression resides within the CD95 gene promoter, and does not require the previously defined intronic wt p53RE.
In recent years, it has become clear that many tumorassociated p53 mutants can bind and inactivate also the other members of the p53 family, namely p63 and p73 (Di Como et al., 1999; Marin et al., 2000; Strano et al., 2000; Gaiddon et al., 2001; Strano et al., 2002) . At least for p73, the efficacy with which mutant p53 exerts this dominant negative effect has been shown to depend to a great extent on the identity of the residue located at position 72 of human p53. Owing to a common polymorphism, normal individuals can carry either a proline or an arginine at that position. However, when p53 undergoes a mutation within its DNA binding core domain, the presence of Arg at position 72 leads to a much stronger inhibition of p73 function than a Pro at position 72 . Of note, this difference has been demonstrated convincingly for the two polymorphic versions of p53R175 H . We therefore compared the extent of repression of the CD95 promoter by these two polymorphic variants. As seen in Figure 5a the 72P isoform was at least as effective as its 72R counterpart; in fact, in repeated experiments, 72P appeared consistently more potent in repressing CD95-luc activity (Figure 5a and data not shown). Since 72P is expected to be impaired in its ability to inactivate endogenous p73 , and probably also p63, our data suggest that inhibition of CD95 gene expression by mutant p53 may occur independent of interactions with other p53 family members.
Additional support for this conclusion was obtained through the use of a dominant negative fragment of p73, denoted p73DD; this truncated protein oligomerizes with full length, transactivation-competent forms of p73 and interferes with their activity ; furthermore, p73DD also inactivates transactivation-competent forms of p63 (Y Daniely and M Oren, data not shown). As Figure 5b , p73DD failed to repress the CD95 promoter, although it effectively blocked the induction of several p53-responsive promoters, including the CD95 promoter, under similar experimental conditions (data not shown). This further argues that the basal level of CD95 promoter activity in this experimental system is not dependent on endogenous p63 or p73, and thus the effect of mutant p53 must be exerted through some mechanism other than dominant-negative repression of p63 and p73.
Mutant p53 binds preferentially to the CD95 promoter
The mechanism whereby mutant p53 modulates gene expression is presently unclear. We wished to investigate the possibility that mutant p53 can interact, directly or indirectly, with specific regulatory elements within the CD95 gene. To this end, a membrane-based protein-DNA binding assay ('Southwestern blotting') was utilized. In brief, various types of DNA, mostly as luciferase reporter plasmids, were immobilized to nitrocellulose membranes. Each membrane was then reacted with an extract of H1299 cells transfected with expression plasmids for either wt p53 or p53R175 H, or control empty vector. Bound p53 was revealed with p53-specific antibodies.
The results are shown in Figure 6a . As expected, wt p53 bound strongly to the p21 promoter and to a double-stranded DNA oligonucleotide comprising the consensus p53-binding site (el-Deiry et al., 1992), whereas mutant p53R175 H failed to exhibit significant binding to these same DNAs. In line with its ability to activate the MDR1 promoter (Chin et al., 1992; Strauss and Haas, 1995; Sampath et al., 2001) , mutant p53 was found to bind preferentially to this promoter. Mild MDR1 promoter binding was also displayed by wt p53, and may account for the ability of wt p53 to repress transcription from this promoter (Chin et al., 1992) . In agreement with its reported interaction with the human CD95 gene (Muller et al., 1998) , wt p53 bound well to the plasmid containing a combination of the CD95 promoter and intronic p53RE [CD95(P þ I)], as well as to a plasmid in which the CD95 intronic element was Figure 6 Mutant p53 binds the CD95 gene promoter. (a) H1299 cells were either transiently transfected with wt p53, or stably transfected with either p53R175 H or pCMV-neo-Bam, serving as a vector control. Nuclear extracts were prepared from each cell population, brought to a final concentration of 0.5 mg/ml, and incubated with nitrocellulose membrane squares spotted and crosslinked with 300 ng DNA of each of the indicated plasmids. pBlueScript served as an irrelevant control plasmid, pGL3 is the basic luciferase reporter plasmid serving for insertion of the various transcriptional control elements, and p53RE is a synthetic oligonucleotide carrying the consensus p53-binding element (elDeiry et al., 1992). p21-luc and MDR1-luc carry the promoters of the indicated genes in front of luciferase. CD95(P þ I)-luc is identical to CD95-luc of Figure 3a , and harbors both the CD95 promoter and the p53-binding region from intron 1 of the CD95 gene. CD95(Ps)-luc carries only the CD95 promoter, whereas CD95(I þ SV)-luc carries the intronic p53-binding element of the CD95 gene followed by an SV40 minimal promoter (Muller et al., 1998) . All squares within a single vertical column were physically located on the same single membrane, and are depicted as distinct separate squares for the sake of clearer presentation. Each membrane square was probed with a p53-specific polyclonal serum, and developed with the ECL kit (Amersham). (b) Extracts from H1299 cells transfected with vector control (lane 2) or with expression plasmids for either wt p53 (lane 4) or mutant p53R175 H (lanes 1,3) , were subjected to CHIP using p53 polyclonal antibodies, as described under Materials and methods. The presence of CD95 genomic sequences (either CD95 upstream promoter region or CD95 intron I) was subsequently detected by performing PCR reactions with the immunoprecipitated genomic DNA. Lane 1 -control CHIP performed in the absence of p53 antibodies on H1299 cells transfected with p53R175 H. Lane 5 -positive PCR control reaction carried out on 0.1% of the genomic DNA extracted from an equivalent amount of H1299 cells without any CHIP step
--------------------------------------------------------"
Mutant p53 represses CD95(Fas/APO-1) expression
A Zalcenstein et al linked to a minimal SV40 promoter instead of the CD95 promoter [CD95(I þ SV)]. It can be noted that wt p53 also exhibited some binding to the CD95 promoter [CD95(Ps)], supporting the possible existence of one or more weak p53REs within the CD95 promoter (Muller et al., 1998) . Importantly, p53R175 H bound efficiently to the CD95 regulatory sequences [CD95(P þ I)]; the signal intensity was comparable to that obtained with wt p53. Further mapping revealed that this interaction targets the upstream promoter [CD95(Ps)], rather than the intronic region containing the wt p53RE. This is consistent with the fact that the CD95 promoter is repressed by mutant p53 in reporter assays (Figure 4f) .
To determine whether mutant p53 associates with the CD95 promoter also within living cells, chromatin immunoprecipitation (CHIP) analysis was performed. H1299 cells expressing either no p53 at all, or p53R175 H or wt p53, were crosslinked, harvested, and subjected to CHIP with an anti-p53 polyclonal antibody, followed by RT-PCR analysis with primer pairs derived either from the CD95 promoter (about 1 kb upstream of the transcription initiation site), or from the intronic region spanning the wt p53RE of the CD95 gene. The results are shown in Figure 6b . As expected, wt p53 was found to be associated specifically with the region containing the p53RE (lane 4). Mutant p53, on the other hand, showed no in vivo binding to the intronic p53RE; instead, it exhibited selective binding to the CD95 promoter region (lane 3).
Taken together, these findings imply that the mechanism mediating the inhibitory effect of mutant p53 on CD95 gene transcription is distinct from that underlying the stimulatory effect of wt p53 on the same gene. Moreover, our observations lend strong support to the conjecture that the selective physical association of mutant p53 with the CD95 promoter underlies its ability to repress CD95 gene expression.
Discussion
The data presented in this study demonstrate that, in the presence of mutant p53, the CD95L-CD95 apoptotic pathway is markedly attenuated. This is likely to be due, at least in part, to repression of CD95 gene transcription by mutant p53. The data further suggest that such repression may rely on the binding of mutant p53 to the CD95 promoter, in a region distinct from the intronic site serving as the primary binding target of wt p53 in the CD95 gene.
Our findings may help explain some recent observations relating to the expression of CD95 in human cancer. Thus, a survey of nonsmall cell lung carcinoma tumors revealed a strong correlation between the presence of p53 mutations and reduced CD95 mRNA levels (Boldrini et al., 2001) . Similarly, p53 mutations in hepatocellular carcinoma were shown to correlate with loss of CD95 expression, measured by immunohistochemistry (Volkmann et al., 2001) . Interestingly, the latter study suggested that reduced CD95 expression is characteristic of tumors harboring only some, but not all, forms of mutant p53. Our findings predict that this observation may be explained by a differential capacity of distinct p53 mutants to downregulate CD95 promoter activity. It is noteworthy that common tumor-associated p53 mutants indeed differ markedly with regard to their antiapoptotic gain of function (Blandino et al., 1999) . At least for three hot-spot mutants, p53R175 H, p53R273 H and p53R248W, differential inhibition of drug-induced apoptosis correlates well with differential repression of the CD95 promoter: p53R175 H is an effective inhibitor of apoptosis and CD95 promoter activity, whereas both p53R273 H and p53R248W inhibit apoptosis (Blandino et al., 1999) and CD95 promoter activity (Figure 4d ) to a lesser degree than p53R175 H. This suggests that a common mechanism may underlie both these activities of mutant p53. This conclusion is also supported by the apparent requirement of the N-terminal transactivation domain for both CD95 repression (Figure 4b ) and cytoprotection (Matas et al., 2001 ) by mutant p53.
Our findings also provide several clues on the molecular mechanism whereby mutant p53 represses CD95 transcription. One likely explanation might have been that mutant p53 exerts its impact on the CD95 promoter owing to its ability to bind and inactivate transcription-competent (TA) forms of the p53 family members p63 and p73 (Di Como et al., 1999; Marin et al., 2000; Strano et al., 2000; Gaiddon et al., 2001; Strano et al., 2002) . Indeed, TAp73 can activate transcription from the CD95 promoter/intronic p53RE in transient transfection assays (M Mu¨ller, G Melino and PHK, in preparation). Thus, if p73 or p63 plays a role in maintaining basal CD95 mRNA levels, their inactivation by excess mutant p53 might explain our observations. Although we cannot presently rule out completely a contribution of this mechanism to our results, the data in Figure 5 argue strongly at least against its being the only explanation. Moreover, we did not observe significant differences between the R72 and P72 isoforms of p53R175 H with regard to their ability to augment the resistance of H1299 cells to killing by etoposide (data not shown), further suggesting that both repression of CD95 transcription and inhibition of DNA-damage induced apoptosis by mutant p53 do not rely on inactivation of endogenous p73, and perhaps also p63. Thirdly, activation of CD95 gene expression by TA forms of p63 and p73 is expected to rely on the interaction of these proteins with the intronic p53RE; yet, mutant p53-mediated repression is independent of the p53RE (Figure 4f ). All these argue in favor of a repression mechanism that relies on some other molecular property of mutant p53, distinct from its dominant-negative effect on TA isoforms of p53 family members.
Indeed, we found a physical interaction between mutant p53 and regulatory elements within the CD95 promoter. Such a specific interaction could be confirmed to occur not only in vitro (Figure 6a ), but also within living cells (Figure 6b ). As the experiment in Figure 6a was performed with crude nuclear extracts rather than with purified mutant p53, the data do not prove direct binding of mutant p53 to CD95 promoter DNA. It thus remains to be established whether mutant p53 recognizes directly specific sequence elements within the CD95 DNA, or rather is tethered to them through protein-protein interactions with one or more DNAbinding proteins. Of note, activation of the MDR1 promoter by mutant p53 has been shown to require its association with transcription factors of the ETS family (Sampath et al., 2001) . Either way, it is reasonable to assume that the ability of mutant p53 to associate with the CD95 promoter underlies the repression of this promoter.
Our findings may have important clinical implications. In view of the observations that CD95 activity is required for the efficient killing of many types of tumor cells by chemotherapy (Friesen et al., 1996; Muller et al., 1997; O'Connor et al., 2000; Shao et al., 2001) , downregulation of endogenous CD95 expression by mutant p53 proteins, often accumulated in cancer cells, might contribute to increased chemotherapy resistance. Furthermore, it is highly conceivable that this inhibitory effect of mutant p53 is not restricted to the CD95 gene. There may thus exist additional proapoptotic genes whose expression is downregulated by mutant p53, further contributing to a worse patient outcome. While such additional mutant p53 target genes remain to be identified, one might predict that interfering with the expression or function of mutant p53 in tumor cells may render such tumors more responsive to therapy and perhaps reduce their aggressiveness and metastatic capacity.
Materials and methods
Cells, plasmids, infections and transfections
H1299 cells were obtained from ATCC. H1299 cells were maintained in an RPMI medium (Sigma) supplemented with 10% fetal calf serum (FCS, Sigma). PC3 cells were maintained in Dulbecco's modified Eagle medium (DMEM, Gibco) supplemented with 10% FCS.
Plasmid pCMV-neo-Bam-p53R273 H and expression plasmids for p53R175 H, carrying either Arg or Pro at position 72, were obtained from B Vogelstein and W Kaelin, respectively. A pcDNA3-based expression plasmid for p53R175H (22, 23) was constructed by G Blandino. Luciferase reporter plasmids carrying various portions of the human CD95 gene have been described before (Muller et al., 1998) . Plasmid pM5neo-ecotropic-R, encoding the mouse ecotropic receptor was provided by S Benchimol.
Infections for FACS, real-time PCR analysis, and surface CD95 protein quantification were carried out using a standard protocol. Briefly, PC3 cells were stably transfected with pM5neo-ecotropic-R, encoding the mouse ecotropic receptor, and selected for two weeks in 0.4 mg/ml G418. Concurrently, 293 T cells were transfected with the retroviral construct pBabe-175 H, using JetPEI (Polyplus transfection) according to the manufacturer's instructions. Virus-containing culture supernatants were harvested 24-48 h post-transfection at 6 h intervals and pooled together. The stably transfected PC3 cells were then infected with the filtered supernatants, and selected for 48 h in 40 mg/ml of puromycin, resulting in cell populations stably expressing mutant p53R175 H. For luciferase assays, all cells were seeded and transfected using Fugene (Roche) at a ratio of 2 mg DNA:3 ml Fugene, according to the manufacturer's instructions.
FACS analysis of CD95 surface protein
Noninfected PC3 cells and cells infected with mutant p53R175 H were plated in six-well dishes. At 24 h after plating, cells were trypsinized and washed once in PBS. Cells were then incubated with an anti-CD95 monoclonal antibody (BMS140, Bender) for 1 h, washed, and incubated for 30 min with a Cy-5 conjugated goat-anti-mouse secondary antibody (Jackson). Cells were then placed on ice and analysed by FACS.
Nuclear extracts
Nuclear extracts were prepared as described (Offer et al., 1999) . Cells (10 6 -10 7 ) were washed twice with cold PBS and harvested. Cell pellets were resuspended by gentle pipetting in 400 ml of buffer A (10 mm HEPES-KOH pH 7.9; 1.5 mm MgCl 2 ; 10 mm KCl; 0.5 mm DTT; 0.2 mm PMSF; 10 mg/ml leupeptin; 1 mg/ml pepstatin and 10 mg/ml aprotinin). After 15 min incubation on ice, 25 ml of 10% NP-40 was added and vortexing was performed vigorously for 10 min. After centrifugation, cell pellets were resuspended in 150-300 ml of buffer C (20 mm HEPES-KOH pH 7.9; 25% glycerol; 420 mm NaCl; 1.5 mm MgCl 2 ; 0.2 mm EDTA; 0.5 mm DTT; 0.2 mm PMSF; 10 mg/ml leupeptin; 1 mg/ml pepstatin and 10 mg/ml aprotinin). Tubes were transferred to a rotating platform for 15 min at 41C, and then centrifuged and the protein content of the supernatant determined by the Bradford procedure. Aliquots were stored at À701C.
Western blot analysis
Cells were lysed in passive lysis buffer (Promega). Lysate aliquots were resolved by SDS-PAGE on a 10% polyacrylamide gel, transferred onto a nitrocellulose membrane, and probed sequentially with a mixture of the p53-specific monoclonal antibodies PAb1801 and DO-1, followed by antivinculin antibody (Sigma). Membranes were then reacted with secondary goat-anti-mouse HRP-conjugated antibodies (1:10 000, Jackson), and developed using the ECL kit (Amersham).
'Southwestern' analysis
In total, 300 ng of each DNA sample was mounted onto a nitrocellulose membrane and crosslinked with 120 J/m 2 of UVC light. Membranes were washed twice in PBS and blocked with 5% skim milk in PBS for 3 h. Nuclear extracts were prepared as described, and diluted to a protein concentration of 0.5 mg/ml in gel-shift buffer (12.5 mm Tris-HCl pH 7.9; 3.1 mm MgCl 2 ; 25mm KCl; 0.5 mm DTT; 10% glycerol; 0.25 mm EDTA; 0.2 mm PMSF; 10 mg/ml leupeptin; 1 mg/ml pepstatin, 10 mg/ml aprotinin and 1 mg/ml of pGL3-basic plasmid DNA for blocking). Nuclear extracts were incubated overnight at 41C with the membrane segments, followed by 3 Â 5 min washes in PBS-T. The membrane was next incubated for 1 h with a p53-specific polyclonal serum under standard Western blot analysis conditions, followed by three consecutive 5 min washes in PBS-T and incubation for 30 min with horseradish peroxidase-conjugated goat-anti-rabbit secondary antibody. The membranes were then developed with an ECL kit (Amersham).
CHIP analysis
CHIP was performed essentially as described previously (Weinmann and Farnham, 2002) , except that lysates from 3 Â 10 7 H1299 cells stably expressing p53R175 H or transiently transfected with wt p53 were diluted fivefold in a CHIP dilution buffer (0.01%. SDS, 1.1% Triton X-100, 1.2 mm EDTA, 16.7 mm Tris pH 8.1, 167 mm NaCl), and bound complexes were collected with protein A-agarose beads crosslinked to anti-p53 rabbit polyclonal antibody by DMP (Bailon et al., 2000) . PCR of the CD95 intronic p53RE (wt p53-binding site) was performed on immunoprecipitated chromatin using the following pair of oligonucleotide primers: 5 0 -GGATAATTAGACGTACGTGGGC-3 0 (forward) and 5 0 -GGACAATTGACAAAATCAGTATC-3 0 (reverse). PCR of the CD95 promoter (mutant p53-binding site) was performed using the oligonucleotides 5 0 -CCGCTGGGCA-GGCGGGGCAGCTCC-3 0 (forward) and 5 0 -TGCAGGCT-CTCTCCCCGCCCCCGC-3 0 (reverse).
Luciferase assays
Luciferase assays were performed using (d)-luciferin (Roche). Luminescence was determined with the aid of a Rosys-Anthos Lucy 3 luminometer.
Apoptosis assays
An expression vector for soluble CD95L (lz-FASL) was designed similar to the plasmid used for preparing soluble CD40L (Fanslow et al., 1994) . Briefly, CD95L was fused to a mutant leucine zipper (LZ) domain of the yeast transcription factor GCN4. In total, 293 cells were transfected with the CD95L expression vector, and the medium collected 3 days later as a source of CD95L.
For analysis of apoptosis by PI exclusion, cells were washed twice with PBS, treated for 1 min with 0.05% trypsin-EDTA solution (Bet-Haemek, Israel), and rapidly washed again with PBS. Cells were dislodged from the dish by pipetting, centrifuged and resuspended in PBS containing 1 mg/ml PI (Sigma) for 30 min before being analysed with the aid of a FACSORT double laser flow cytometer.
Real-time RT-PCR analysis
Total RNA was extracted using the Nucleo-Spin RNA II kit (Macherey Nagel). In total, 2 mg of each RNA sample was reverse transcribed using MMLV reverse transcriptase (Promega). Real-time PCR was performed on a Roche Lightcycler system using CD95-specific primers (sense: CAAGGGG-GAATTGAGGA, antisense: CACTTGGTGTTGCTGGT-GAG) to yield a 150 bp PCR product. A touch-down PCR method was employed, where the annealing temperature is gradually reduced by 0.51C each cycle during the first 16 cycles (from 65 to 571C), in order to increase CD95 primer specificity. cDNA levels were normalized to GAPDH, amplified with appropriate primers (sense: ACCACAGTCGCCATCAC, antisense: TCCACCACCCTGTTGCTGTA), yielding a 400 bp product.
